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Abstract
Background: To evaluate the effect of a smoking-, alcohol- or combined-cessation intervention starting shortly
before surgery and lasting 6 weeks on overall complications after radical cystectomy. Secondary objectives are to
examine the effect on types and grades of complications, smoking cessation and alcohol cessation, length of hospital
stay, health-related quality of life and return to work or habitual level of activity up to 12 months postoperatively.
Methods/design: The study is a multi-institutional randomised clinical trial involving 110 patients with a risky alcohol
intake and daily smoking who are scheduled for radical cystectomy. Patients will be randomised to the 6-week Gold
Standard Programme (GSP) or treatment as usual (control). The GSP combines patient education and pharmacologic
strategies. Smoking and alcohol intake is biochemically validated (blood, urine and breath tests) at the weekly
meetings and at follow-up.
Discussion: Herein, we report the design of the STOP-OP study, objectives and accrual up-date. This study will
provide new knowledge about how to prevent smoking and alcohol-related postoperative complications at the
time of bladder cancer surgery. Till now 77 patients have been enrolled. Patient accrual is expected to be finalised
before the end of 2017 and data will be published in 2018.
Trial registration: ClinicalTrials.gov, ID: NCT02188446. Registered on 28 May 2014.
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Background
Postoperative morbidity after radical cystectomy is fre-
quent despite the implementation of fast-track care
pathways and robotic-assisted cystectomy [1]. Complica-
tion rates vary from 30 to 64% even in high-volume cen-
ters [2, 3]. Common complications include infections,
ileus and impaired wound healing, all of which are bur-
densome for the individual patient and costly for society.
Daily smoking and risky alcohol intake (more than
two drinks daily) both increase the risk of postoperative
morbidity and cancer [4–6]. Smoking is also the major
and most modifiable risk factor for development of blad-
der cancer in both men and women [7].
Intensive smoking- and alcohol-cessation intervention
6–8 weeks before elective surgery reduces the incidence
of postoperative morbidity to about half [8–10]. Postop-
erative smoking-cessation interventions in elective sur-
gery and after fracture surgery might likewise reduce the
development of complications [11, 12].
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Preoperative intervention lasting 6–8 weeks prior to
cancer surgery is, however, unfeasible given the ongoing
efforts to accelerate diagnosis and treatment of patients
at suspicion of having cancer. In Denmark, the time-
frame for intervening before cancer surgery is maximum
14 days, often less, which renders longer-lasting pre-
operative intervention impossible today. Furthermore, a
programme with one preoperative meeting has shown
no effect on surgical risk reduction for other groups of
cancer patients undergoing surgery [8, 13]. Currently,
standard care, therefore, includes written information
about the risks of smoking and alcohol in relation to
surgery without proactive intervention or systematic re-
ferral to cessation services.
Hypothetically, intensive smoking- and alcohol-cessation
intervention initiated at the earliest possible time before
surgery, and continued for 5 weeks after surgery, could
benefit patients undergoing radical cystectomy. Interven-
tion during this period might to some degree improve
pathophysiological mechanisms, such as tissue perfusion
and oxygen delivery, ciliary and immune function, surgical
stress response, arrhythmias and bleeding time [14–17], all
of which are beneficial for postoperative recovery. Findings
of physiological studies have shown that most of the
smoking-induced changes are reversible to some degree,
and that the period needed for a substantial improvement
is about 6–8 weeks [18, 19]. To our knowledge, the
surgical studies on smoking and alcohol intervention for
risk reduction have focussed only on either smoking or al-
cohol cessation in isolation. Since smoking and alcohol
drinking often coexist and alcohol use is associated with
increased risk of smoking relapse [20, 21], it would be rele-
vant to intervene on both.
The aim of this randomised study is, therefore, to
evaluate the effect of a smoking, alcohol or combined
cessation intervention starting shortly before surgery,
and lasting 6 weeks, on overall complications after rad-
ical cystectomy. Secondary objectives are to examine the
effect on types and grades of complications, smoking
cessation and alcohol cessation, length of hospital stay,
health-related quality of life and return to work or habit-
ual level of activity up to 12 months postoperatively.
Methods/design
An ongoing multicenter, randomised clinical trial with
1:1 ratio allocation of participants to either: (1) smoking
and/or alcohol cessation intervention initiated 1–2
weeks before radical cystectomy and lasting for a total of
6 weeks, or (2) treatment as usual (Fig. 1). The study
was initiated in November 2014 and till now 77 patients
have been enrolled (Table 1), an average of two to three
patients per month. We aim to enrol a total of 110 pa-
tients with expected completion of patient accrual in
November 2017.
Fig. 1 Trial profile
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The protocol for this randomised clinical trial is re-
ported in compliance with the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
guidelines [22]. See Additional file 1.
Settings
Currently, all university-affiliated specialised urological
centers performing radical cystectomy in Denmark are
participating in the trial in order to ensure adequate par-
ticipant enrolment. Together, they perform approxi-
mately 300 radical cystectomies annually.
Inclusion criteria
Patients scheduled for radical cystectomy for bladder
cancer and who smoke daily and/or drink at least 3 units
of alcohol daily. One unit contains 12 g ethanol.
Exclusion criteria
Exclusion criteria are: cognitively unable to provide in-
formed consent; allergy to disulfiram, benzodiazepines
or Nicotine Replacement Therapy (NRT); pregnancy and
breastfeeding.
Research procedures
In connection with the initial planning of surgery, the
patient’s designated urologist and a trial nurse approach
eligible patients with information about the study and
the invitation to participate. Trial nurses at each site
randomise patients using a computer-generated, strati-
fied, block randomisation scheme [23]. The randomisa-
tion system is accessible around the clock via tablets.
This ensures immediate randomisation of patients
accepting participation and adequate allocation conceal-
ment. Block sizes vary from 2 to 8. Stratification takes
place for trial site and smoking, risky alcohol drinking or
both.
Intervention
Patients allocated to the intervention group receive five
counselling sessions before and after surgery over
6 weeks with trained smoking- and alcohol-cessation
counsellors. Nine registered nurses from the participat-
ing sites who have taken part in a 4-day educational
programme followed by practical training in the Gold
Standard Programme (GSP), provide the intervention
(see Table 2) [24]. The project leader (SVL) of the trial
ensures that all counsellors follow the principles of the
GSP programme by discussion of the intervention regu-
larly. The principles of motivational interviewing, bal-
anced decision-making and the trans-theoretical model
of change are the underlying tenets of the programme
[25]. These principles describe a general approach to
assessing patients’ empowerment using three main tools:
the LINE, the BOX and the CIRCLE (see Figs. 2 and 3).
Together, the LINE and the BOX facilitate contempla-
tion of change in patients and establish a common
ground for supporting change. The CIRCLE is a model
representation of the stages that people go through dur-
ing the process of change. It primarily helps the
counsellor to choose how best to support the patient.
At the first meeting the surgical patient is educated
about the association between smoking and alcohol in-
take and the increased risk of postoperative complica-
tions. To get the longest period of preoperative
quitting the patient is encouraged and supported to
quit already at the first meeting. At the second meeting
the education focusses on addiction and withdrawal
symptoms. Patients may develop stress caused by ab-
stinence from smoking and drinking. In the 6-week
intervention period smokers are offered a personalised
Nicotine Replacement Therapy (NRT) schedule de-
vised in accordance with patient preferences and nico-
tine dependency assessed by the Fagerström’s Test for
Nicotine Dependency score [26]. Risky drinkers are
Table 1 Accrual of patients to date at the five participating
institutions
Institutions Accrual, n
Rigshospitalet, University Hospital of Copenhagen 45
Herlev, University Hospital of Copenhagen 13
Skejby, University Hospital of Aarhus 13
Aalborg University Hospital 5
Odense University Hospital 1
Table 2 Gold Standard Programme for smoking and alcohol
cessation intervention
Patient education programme
First meeting (before admission)
◦ Level of motivation, ambivalence, pros and cons
Second meeting (after 1 week)
◦ Dependence, withdrawal symptoms (experience and expectations)
Third meeting (after 2 weeks)
◦ Relapse (description and management)
Fourth meeting (after 3 weeks)
◦ Benefits of short- and long-term smoking and/or alcohol abstinence
Fifth meeting (after 5 weeks)
◦ Continued smoking abstinence and/or reduced alcohol intake
following intervention
At each meeting:
Smokers: personalised Nicotine Replacement Therapy (NRT) in
accordance with patient preferences and nicotine dependency
Risky drinkers: thiamine and B vitamins (300 mg × 7 weekly)
Alcohol withdrawal prophylaxis and treatment (chlordiazepoxide
10 mg as required)
Disulfiram (200 mg × 2 weekly) supervised at weekly meetings (not
administrated if patients test positive on breath test)
All: haemoglobin, liver enzymes and alcohol biomarkers (blood, urine),
carbon monoxide (CO) and alcohol breath test, lung function test
The study medication is provided for free and transportation for the
weekly meetings will be reimbursed. Patients have telephone access to
the research nurse
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offered supportive medical treatment against develop-
ment of mild to moderate withdrawal symptoms
(chlordiazepoxide 10 mg, max times 10). In addition,
some of the stress is expected to be reduced by the
empathic intervention. At the third meeting focus is
on relapse management after discharge. At the fourth
meeting other benefits of short- and long-term abstin-
ence are on the agenda. At the fifth meeting future
lifestyle is discussed together with present experiences
and coming challenges and patients are encouraged to
continued smoking abstinence and a low alcohol intake
within national recommendations.
At each meeting patients are asked if they have experi-
enced side effects of the pharmacological support. Po-
tentially unknown side effects are reported and, if
serious, may lead to early termination of the trial.
The study medication is provided for free. All
meetings are planned in connection with scheduled
visits in the outpatient clinic or at admission to hos-
pital if possible. Patients can contact the research
nurse via phone.
Standard care
Apart from information about the background, objec-
tives and potential implications of the current trial, pa-
tients allocated to standard care receive the national
folders on alcohol and tobacco and surgery. This entails
written information about the risks of smoking and
drinking in relation to surgery according to national
guidelines. Patients are ensured that they are free to ac-
cess smoking-cessation and/or alcohol-cessation support
services in the hospital or elsewhere if they wish. Stand-
ard care patients are breath-tested for exhaled carbon
monoxide (CO) and alcohol at baseline and follow-up
postoperatively (see Fig. 4).
For both groups
Both groups receive routine procedures regarding gen-
eral patient information, thromboembolic prophylaxis
and antibiotics, anaesthesia, surgical intervention and
postoperative care according to the clinical guidelines
used at each institution.
Fig. 2 The line for identification and the box for assessing ambivalence
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In order to find out if patients who decline to partici-
pate in the trial differ from those who are enrolled, we
ask for permission to follow their perioperative course in
the medical journal. Those who accept are asked to pro-
vide informed consent.
Measurements
The primary and secondary outcomes will be evaluated
at follow-up points after 6 weeks, 3, 6 and 12 months
after surgery (see Fig. 4). All trial data are fed into an
electronic Case Report File and will be monitored for
completeness. Blood and urine samples are analysed at
Labmedicin Skåne, clinical chemistry, Lund, Sweden.
Objectives of the STOP-OP trial
Postoperative morbidity
The primary outcome is the proportion of patients who
develop any postoperative complication, or death, within
30 days after surgery. Secondary outcomes are: types
and grades of complications within 30 and 90 days after
surgery assessed using the Clavien-Dindo classification
[27] of surgical complications. Evaluation of postopera-
tive complications is performed prospectively through
patient interviews at all follow-up meetings and
retrospectively by a urologist unaware of the patients’
group allocation.
Previous studies of intensive preoperative smoking
cessation interventions report 65% and 49% reductions
in overall postoperative complications [10–12], and pre-
operative alcohol cessation interventions a 74% reduc-
tion [9]. We assume that 50% of the project patients
develop one or more complications after radical cystec-
tomy. Our aim is to reject or confirm a reduction in the
number of patients who develop any postoperative com-
plication from 50% to 25%. With a type-1 error risk of
5% and a type-2 error risk of 20% (80% power), the re-
quired sample size is 55 patients in each group.
Smoking and alcohol cessation
At baseline and at all meetings and follow-up visits,
haemoglobin, liver function tests and alcohol biomarkers
(carbohydrate-deficient transferrin (CDT) and phospha-
tidylethanol (PEth)) are determined in both the interven-
tion and control groups. In addition, breath tests
measuring alcohol and CO are done. During the inter-
vention, patients report alcohol and/or tobacco use in a
log book. Duration of self-reported and validated con-
tinuous smoking and/or alcohol abstinence up to
12 months after surgery is reported.
Fig. 3 The stages of change model
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Length of hospital stay (LOS)
Length of stay is used as a surrogate for recovery after
surgery. We measure number of days from surgery (day
0) till discharge and also number of days in hospital
within 90 days after surgery.
Other outcomes
HRQoL
We measure health-related quality of life (HRQoL) out-
comes using the generic questionnaire EuroQol-5D (EQ-
5D) at baseline and postoperatively at 6 weeks, 3, 6 and
12 months after surgery. In addition, we use the disease-
specific European Organisation of Research and Treat-
ment of Cancer Questionnaires EORTC-QLQ-C30 and
QLQ-BLM30 for patients with bladder cancer at base-
line and postoperatively at 6 and 12 months.
Time to return to work or habitual level of activity is a
surrogate for recovery after surgery and will be evaluated
within 12 months after surgery.
Statistics
The data are not expected to be normally distributed, so
nonparametric tests are performed. Continuous variables
are presented as medians and ranges or means and
standard deviations (SD) as appropriate. Categorical
variables are presented as counts. Their associated 95%
confidence intervals (CI) and p values will be provided.
The effect of the intervention on risk of postoperative
complications and smoking/alcohol abstinence is ana-
lysed by Fisher’s exact test. Estimates of the difference
between treatment groups will be reported as relative
risks (RR) with 95% confidence intervals and p values.
Effects of the intervention on LOS and HRQoL scores
are analysed by Mann-Whitney’s U test. Analysis adjusting
for institution is also performed by logistic regression
models. Effects are considered statistically significant if p
values are less than 0.05.
We will conduct all analyses using intention-to-treat
principles. All analyses are done blinded by an independ-
ent researcher. We will use R 3.2.2 [28] to perform all
analyses.
Discussion
The randomised design provides evidence on the highest
possible level regarding the effect of an intensive smoking-
and/or alcohol-cessation intervention on complications
after bladder cancer surgery. Blinding of patients and pro-
ject staff is not possible or intended as the intervention in-
cludes patient education to support abstinence. However,
evaluation of postoperative complications is performed
Fig. 4 Time schedule for enrolment, interventions and assessments
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blinded by a urology specialist unaware of the patients’
group allocation. Also, the statistical analyses are done
blinded by an independent researcher.
Recruitment of patients to the trial is expected to be
challenging, as the proportion of bladder cancer patients
in Denmark who are current smokers is about 30% [29].
Table 1 shows the difference in recruitment rates among
our centres. Previous studies report widely varying par-
ticipation rates in preoperative smoking cessation inter-
ventions ranging from 31 to 96% [8]. The number
needed to screen to get one eligible patient to accept
participation in alcohol-intervention studies varies from
a few up to 70 patients. However, the rates do not differ
between RCTs and non-RCTs, or between brief and in-
tensive alcohol-intervention studies [30]. A strength in
this study is that we follow common research practice
and assess both 7-day-point-prevalence-rates and con-
tinuous abstinence during the intervention period vali-
dated by biochemical tests. These are regarded as valid,
replicable outcome measures and less likely to be biased
by faulty recall [31, 32].
This is the first trial to evaluate the effect of both a
smoking- and alcohol-cessation intervention on postop-
erative complications in patients undergoing cancer sur-
gery and thus provides much needed level-1 evidence in
this area. From a clinical perspective this may help to
improve postoperative outcome and also address the im-
plications of risky drinking and smoking in cancer
surgery. From a patient perspective, an optimised peri-
operative course may minimise any short-term negative
impact of surgery on HRQoL. A 6-week period of ab-
stinence from tobacco and alcohol could reduce risky
alcohol drinking and motivate long-term smoking cessa-
tion and thus benefit psychological HRQoL [33]. From a
socioeconomic perspective a potential reduction in post-
operative complications would impact the use of health
care services and result in cost-savings both in the short
and long term. The results from the STOP-OP study will
be published in both scientific journals and patient-
directed journals.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents*. (DOC 121 kb)
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